Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia

Jingying Cuia School of Medicine, Wuhan University of Science and Technology, Wuhan, People’s Republic of China;b Department of Hematology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, People’s Republic of ChinaView further author information

Xuexing Chenb Department of Hematology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, People’s Republic of ChinaView further author information

Chunfang Lib Department of Hematology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, People’s Republic of ChinaView further author information

Qiong Yanb Department of Hematology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, People’s Republic of ChinaView further author information

Guolin Yuanb Department of Hematology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, People’s Republic of ChinaCorrespondence[email protected]
View further author information

Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia

Supplemental Material

Supplementary Table1.docx

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia

Supplemental Material

Supplementary Table1.docx

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date